ProShare Advisors’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

ProShare Advisors’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-8,744	Closed	-$244K	–	1825
2019 Q3	$244K	Buy	+8,744	New	+$142K	﹤0.01%	1324
2019 Q2	–	Sell	-10,860	Closed	-$97K	–	1671
2019 Q1	$97K	Buy	10,860 +72	+0.7%	+$584	﹤0.01%	1576
2018 Q4	$82K	Sell	10,788 -2,154	-17%	-$34.7K	﹤0.01%	1497
2018 Q3	$271K	Sell	12,942 -458	-3%	-$10.9K	﹤0.01%	1423
2018 Q2	$401K	Sell	13,400 -428	-3%	-$11.7K	﹤0.01%	1228
2018 Q1	$375K	Sell	13,828 -754	-5%	-$22.6K	﹤0.01%	1220
2017 Q4	$420K	Buy	+14,582	New	+$400K	﹤0.01%	1224

ProShare Advisors's DOVA Position: Q4 2019 in Review

ProShare Advisors sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 8,744 shares — an estimated $244K sold.

ProShare Advisors first reported a position in DOVA in Q4 2017 and held it in 7 quarters. The position peaked at $420K in Q4 2017. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

ProShare Advisors reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
ProShare Advisors sold 8,744 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $244K.
ProShare Advisors first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
ProShare Advisors's Dova Pharmaceuticals, Inc. Common Stock position peaked at $420K in Q4 2017.
0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on ProShare Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.